<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6988</article-id>
      <article-id pub-id-type="doi">10.51847/L4h0RW5WCR</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>From Multi-Omics Association to Therapeutically Actionable Targets: A Causal Reasoning Framework for Artificial Intelligence– Enabled Bioinformatics across Molecular Networks, Tissue Contexts, and Disease Heterogeneity</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>Novak</surname>
                <given-names>Clara</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>El-Sayed</surname>
                <given-names>Ahmed</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Kim</surname>
                <given-names>Hana</given-names>
              </name>
                              <xref rid="aff3" ref-type="aff">3</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Nagy</surname>
                <given-names>Peter</given-names>
              </name>
                              <xref rid="aff4" ref-type="aff">4</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Department of Bioinformatics and Multi-Omics Integration, Vienna University of Economics and Business, Vienna, Austria.
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of Computational Biology and Causal Inference, American University in Cairo, Cairo, Egypt.
          </aff>
                  <aff id="aff3">
            <label>3</label>Department of Genomic Medicine and AI-Based Target Discovery, Seoul National University, Seoul, South Korea.
          </aff>
                  <aff id="aff4">
            <label>4</label>Department of Pharmaceutical Bioinformatics and Systems Pharmacology, Corvinus University of Budapest, Budapest, Hungary.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                              E-mail: <email xlink:href="clara.novak@wu.ac.at">clara.novak@wu.ac.at</email>
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>28</day>
        <month>10</month>
        <year>2026</year>
      </pub-date>
      <volume>17</volume>
      <issue>5</issue>
      <fpage>54</fpage>
      <lpage>62</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Multi-omics and artificial intelligence can rank genes, proteins, pathways and molecular states with increasing resolution, yet therapeutic target selection requires a stronger inference than statistical association or predictive relevance. This article develops a causal-reasoning framework for deciding when an omics-supported target claim is sufficiently credible to inform therapeutic progression. The analysis separates five questions that are frequently collapsed: whether the disease-associated signal is assigned to the correct causal gene or molecular entity; whether perturbing that entity is likely to change the disease process in the intended direction; how network structure modifies the consequence of perturbation; whether the mechanism is active in the relevant tissue, cell state and disease stage; and whether disease heterogeneity restricts benefit or introduces harm in particular subgroups. The framework treats actionability as a context-bounded intervention claim rather than a property conferred by cross-omics concordance, network centrality, feature importance or model performance. Evidence can therefore move a target forward, hold it in an exploratory state, restrict it to a conditional domain, or move it backward when counterevidence emerges. The central implication is that multi-omics becomes therapeutically informative only when association is converted into a defensible, revisable account of causal mechanism, intervention direction and context-specific consequence.</p>
      </abstract>
      <kwd-group>
                <kwd>Multi-omics integration</kwd>
                <kwd>Causal inference</kwd>
                <kwd>Artificial intelligence</kwd>
                <kwd>Therapeutic target identification</kwd>
                <kwd>Molecular networks</kwd>
                <kwd>Disease heterogeneity</kwd>
              </kwd-group>
    </article-meta>
  </front>
</article>
